News
iOnctura’s roginolisib awarded Innovation Passport
iOnctura – a company developing treatments for patients with cancer – has announced that the innovative medicine designation, known as the ‘Innovation Passport’, has been awarded for its roginolisib drug by the Medicines and Healthcare products Regulatory Agency (MHRA).